← Browse by Condition
Medical Condition

lung neuroendocrine neoplasm

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for lung neuroendocrine neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — lung neuroendocrine neoplasm Clinical Trials

How many clinical trials are currently recruiting for lung neuroendocrine neoplasm?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for lung neuroendocrine neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lung neuroendocrine neoplasm?
lung neuroendocrine neoplasm research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lung neuroendocrine neoplasm clinical trial?
Eligibility criteria for lung neuroendocrine neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
Roswell Park Cancer Institute 1 trial
Grupo Espanol de Tumores Neuroendocrinos 1 trial

Recruiting Clinical Trials

NCT06202066 Phase 2
Recruiting
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Enrollment
60 pts
Location
United States
Sponsor
Roswell Park Cancer Institute
View Trial →
NCT05918302 Phase 3
Recruiting
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Enrollment
170 pts
Location
Belgium, France, Ita...
Sponsor
Grupo Espanol de Tumores Neuro...
View Trial →

Related Conditions

digestive system neuroendocrine neoplasm (1) malignant solid neoplasm (1) pancreatic neuroendocrine neoplasm (1) neuroendocrine tumors (1) thymus neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology